Nautilus earnings for the third quarter of 2026 included a $15.6 million net loss, wider than the $13.6 million loss a year earlier, as operating expenses rose. The biotechnology company reported $0.2 million in revenue, below an analyst estimate of $0.21 million.

Key Takeaways

  • Operating expenses rose to $16.9 million from $15.5 million in the same quarter of 2025.
  • Nautilus expects to launch its Voyager platform commercially in mid-2027.

Nautilus earnings reflect higher costs

Nautilus Biotechnology released its results on October 27 for the quarter ended September 30, 2026. Revenue was $0.2 million, compared with $0.0 million in the third quarter of 2025.

The quarter’s revenue came primarily from grant income associated with The Michael J. Fox Foundation and service revenue from the Iterative Mapping Early Access Program. The increase in operating expenses was attributed largely to higher laboratory costs, professional services and salaries.

Nautilus reported $114.3 million in cash, cash equivalents and investments.

Voyager launch and research plans

The Seattle-based company is developing a proteomics analysis platform designed to quantify the human proteome for drug discovery, biomarker and clinical research.

Nautilus is participating in SEEDS, a newly funded four-year research consortium focused on using its Voyager platform to study complex diseases including Alzheimer’s and cancer. The initiative is expected to provide up to $6 million in funding. Nautilus also has a goal of delivering 20 assays by mid-2028.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.